Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...

Ozempic has been a hot topic in Hollywood with stars either admitting to using the diabetes drug for weight loss or staunchly ...

Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering ...

Stress hormones, not impaired insulin signaling, may underlie obesity-related diabetes, according to Rutgers research.

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

The global GLP-1 analogues market size was assessed at USD 46.70 billion in 2024. The market is expected to flourish and grow from USD 56.62 billion in 2025 to USD 322.85 billion by 2034, denoting a ...

There’s no hard-and-fast rule for how long it’s safe to stay on Ozempic for weight loss. Novo Nordisk-sponsored studies lasting up to two years show that semaglutide is safe.

The COVID pandemic set in motion trends with alcohol use that have persisted. Disruptions in work, school and lifestyle have ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...